Live Analyst Rating Changes 22494 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Daniel Markowitz CFA
EVR

Daniel Markowitz CFA

Evercore ISI
Wall Street Analyst
★★★★☆
#355
on 13Foresight · ranked by our own returns
64%
Success Rate
+15.4%
Average Return
14 of 22 calls profitable · +10.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 64% of Daniel Markowitz CFA's ratings turned a profit when each position was held for 1 year — averaging +15.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

46 Buy 7 Hold 0 Sell
Daniel's Stock Coverage 10 ratings · 2026-08-11
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
NTRA
Natera
 Aug 07, 2026 BUY Strong Buy
-7.1% avg upside
27 analysts
$360.00
11.68% Upside
 -1.4% ·
PODD
Insulet
 Aug 06, 2026 BUY Strong Buy
+52.6% avg upside
32 analysts
$180.00
27.46% Upside
 +3.3% ·
INSP
Inspire Medical Systems
 Aug 04, 2026 HOLD Buy
+41.8% avg upside
21 analysts
$54.00
10.16% Downside
 -6.0% ·
WST
West Pharmaceutical Services
 Jul 27, 2026 BUY Strong Buy
+3.7% avg upside
18 analysts
$425.00
19.98% Upside
 +7.0% ·
TMDX
TransMedics Group
 Jul 06, 2026 BUY Strong Buy
+17.7% avg upside
15 analysts
$90.00
7.31% Upside
 +15.6% ·
RGEN
Repligen
 Jul 06, 2026 BUY Strong Buy
+6.0% avg upside
25 analysts
$160.00
2.38% Downside
 +9.3% ·
MMED
MiniMed Group, Inc.
 Jun 05, 2026 BUY Strong Buy
+12.8% avg upside
14 analysts
$20.00
2.13% Upside
 +37.7% ·
TECH
Bio-Techne
 May 07, 2026 HOLD Buy
+15.5% avg upside
21 analysts
$50.00
30.83% Downside
 +42.3% ·
DXCM
Dexcom
 Nov 26, 2025 HOLD Strong Buy
+21.4% avg upside
32 analysts
$68.00
19.81% Downside
 +41.7% ·
GH
Guardant Health
 Oct 30, 2025 BUY Strong Buy
-2.5% avg upside
31 analysts
$90.00
46.60% Downside
 +77.0% ·
🔒 5 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Daniel Markowitz CFA — Frequently Asked Questions
How accurate are Daniel Markowitz CFA's stock ratings?
Based on the calls 13Foresight could measure, about 64% of Daniel's ratings were profitable over a one-year hold, with an average return of +15.5% per rating, or +10.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Daniel ranked on 13Foresight?
Daniel Markowitz CFA is currently ranked #355 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Daniel cover?
Daniel most recently has ratings on NTRA, PODD, INSP, WST, TMDX, RGEN, MMED, TECH, DXCM, GH. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.